Review Article

Fetal Growth Restriction Prediction: How to Move beyond

Debora F. B. Leite1,2,3 and Jose G. Cecatti1

1Department of Obstetrics and Gynecology, University of Campinas, School of Medical Sciences, Campinas, Sao Paulo, Brazil
2Federal University of Pernambuco, Caruaru, Pernambuco, Brazil
3Clinics Hospital of the Federal University of Pernambuco, Recife, Pernambuco, Brazil

Correspondence should be addressed to Jose G. Cecatti; cecatti@unicamp.br

Received 23 January 2019; Accepted 1 August 2019; Published 21 August 2019

Academic Editor: Hind A. Beydoun

Copyright © 2019 Debora F. B. Leite and Jose G. Cecatti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The actual burden and future burden of the small-for-gestational-age (SGA) babies turn their screening in pregnancy a question of major concern for clinicians and policymakers. Half of stillbirths are due to growth restriction in utero, and possibly, a quarter of livebirths of low- and middle-income countries are SGA. Growing body of evidence shows their higher risk of adverse outcomes at any period of life, including increased rates of neurologic delay, noncommunicable chronic diseases (central obesity and metabolic syndrome), and mortality. Although there is no consensus regarding its definition, birthweight centile threshold, or follow-up, we believe birthweight <10th centile is the most suitable cutoff for clinical and epidemiological purposes. Maternal clinical factors have modest predictive accuracy; being born SGA appears to be of transgenerational heredity. Addition of ultrasound parameters improves prediction models, especially using estimated fetal weight and abdominal circumference in the 3rd trimester of pregnancy. Placental growth factor levels are decreased in SGA pregnancies, and it is the most promising biomarker in differentiating angiogenesis-related SGA from other causes. Unfortunately, however, only few societies recommend universal screening. SGA evaluation is the first step of a multidimensional approach, which includes adequate management and long-term follow-up of these newborns. Apart from only meliorating perinatal outcomes, we hypothesize SGA screening is a key for socioeconomic progress.

1. Introduction

The intrauterine environment influence on fetus development is a well-known determinant of individual’s long-term health and quality of life. From the initial description of 23 infants being born at term weighing less than 2000 g, Warkany et al. [1] introduced the idea of “intrauterine growth retardation” (IUGR). Soon, they were followed by others [2–4]. They considered IUGR “all conditions leading to a marked reduction in size during intrauterine life” [1], mainly represented by reduced birthweight. Although all of them have described pregnancies and infants with a wide variation of phenotype, with and without hypertensive syndromes or morphologic anomalies, for instance, the turning points were to consider the environment in which the fetus was developing and the placenta role in this process.

In fact, human development goes far beyond genetic inheritance. Lessons learned from pregnancies subjected to smoking [5, 6] or intermittent fasting [7], for instance, show how intrauterine growth is adjustable. Posttranslational changes in small-for-gestational-age (SGA) infants [8] reinforce the thrifty phenotype hypothesis [9]. According to Hales and Barker, the nutritional deficiency, especially regarding amino acids supply, would decrease the pancreatic beta-cells function and induce changes of the muscular, hepatic, and adipose tissue systems functioning, for example [9]. These newborns are at higher risk of neonatal morbidity and mortality [6, 10–18]; in adolescence and adulthood, they present worse neurodevelopment [19, 20] and metabolic [21, 22] and cardiovascular [23] adverse outcomes. On the contrary, the placenta—a shared organ by both the mother and the fetus—is responsible for adjusting maternal supply to the fetus demands. Since it is difficult to realize which are
the normal placental functioning patterns and the optimal fetal growth, it is reasonable to use the birthweight as a measure of the intrauterine environment [24] and SGA newborns as surrogates for fetal growth restriction (FGR) [10–13].

Therefore, considering the long latency of some events, such as cognitive delays and cardiovascular diseases, SGA has impacts of public health magnitude, especially in low- and middle-income countries (LMICs) [13, 25]. In this review, we will discuss the importance of SGA screening in pregnancy and which are the best approaches and moments to perform it.

2. Why We Should Screen for Fetal Growth Restriction?

The identification of FGR as a distinct pathophysiological entity is merged with preterm birth history. In the first half of the 20th century, gestational age at birth and birthweight concepts overlapped; the World Health Organization recommended a birth weight of 2500 g or less to characterize prematurity [26]. However, several authors and clinicians were intrigued by “pseudopremature” newborns, who would be in chronic suffering due to placental insufficiency and would benefit from earlier delivery [2–4]. Only in 1961, the terminology IUGR was first cited [1]. Apart from only birthweight (<2000 g), Warkany et al. suggested that preterm infants whose birthweight were 40% below the expected for a given gestational age should be considered IUGR. Two years later, Battaglia and Lubchenco proposed to use the birthweight as a proxy for intrauterine development [27] and this is still a common practice in the 2000s [10–13], due to difficulties in defining and measuring fetal growth [28–30].

Currently, the birthweight <10th centile, either by population-based or customized charts, is the most accepted definition for SGA infants [28]. This mathematical threshold was initially chosen due to (i) the increased neonatal mortality observed in this group when compared to those born between the 10th and the 90th centiles and (ii) the agreement on the 10th centile among studies up to the 1960s [27]. There are concerns that some of these infants are “constitutionally small,” not at higher risk of (neonatal) adverse outcomes, and lower limits for SGA, such as ≤5th or even ≤2, and 3rd centile [32], are considered by some researchers. However, little is still known about the long-term health endpoints of the “constitutionally small” newborns. Therefore, the 10th centile seems the most suitable cutoff for epidemiological and clinical purposes, and it is the adopted threshold in this review.

The SGA prevalence varies according to the reference standards applied; it tends to be higher with customized curves [11, 12, 14]. Using population-based charts, live births between 19.3% [13] and 27% [25] in LMIC could have been classified as SGA in 2000s. A majority of them were term-SGA (98% and 95.6%, respectively). This turns SGA the most important pregnancy-related syndrome since other pathological conditions, such as pregnancy hypertension and preterm birth, have markedly lower prevalence [11, 12, 14]. It is interesting to note, however, that these “great obstetrical syndromes” may share pathophysiological pathways [33], and it is possible that SGA may represent an underlying condition for the other ones.

The “great obstetrical syndromes” are related to defective deep placentation [33], and studies on placental biomarkers point in this direction [34, 35]. Not surprisingly, pathological placental findings have been related to SGA pregnancies, especially vascular malperfusion lesions, infarction, and chronic villitis of unknown etiology [36–39]. Vascular-mediated changes (e.g., decidual vasculopathy and single or multiple infarctions) usually coexist with Doppler (uterine (UtA), umbilical (UA), or middle cerebral (MCA) arteries) [37, 39] or biochemical abnormalities (such as low levels of placental growth factor (PIGF) [35] or alpha-fetoprotein (AFP): pregnancy-associated plasma protein-A (PAPP-A) ratio >10 [34]). These pathological and functional observations are similar to those found in pregnancies affected by hypertensive disorders, preterm deliveries, and stillbirth [40–44], then possibly reflecting an elementary chronic hypoxia mediating these outcomes.

Additionally, some clinical risk factors are similar between the “great obstetrical syndromes.” Multiple pregnancies and maternal chronic conditions, such as previous hypertension, systemic lupus erythematosus, and diabetes mellitus, are all associated with them [45–47]. Nulliparity [11, 14, 48], shorter height [11, 14, 48], lower pre-pregnancy weight [11, 14, 48] or body mass index [11, 14], previous history of SGA [6, 11, 48], smoking [5, 6, 11, 32, 48], and being born SGA [49] are frequently related to SGA pregnancies. Maternal age shows conflicting results, as well as ethnicity [11, 14], socioeconomic, and marital status [45], which may explain how maternal culture background and environment influence SGA patterns in a given population.

Regarding the outcomes of SGA newborns, extensive investigation has been performed on immediate [10–14, 16, 18, 32, 50] and long-term endpoints [19–23, 51, 52], demonstrating worse health performance at any period of life. Not surprisingly, the leading countries in absolute numbers of fetal and neonatal deaths [53] are the same as SGA [25]: India, Pakistan, and Nigeria. Indeed, growth restriction can account for up to half of the fetal deaths of unknown causes [54], being about 6-fold higher than the chance of stillbirth at term (relative risk, RR, 6.0; 95% CI, 3.1–11.5) [11], or when the birthweight is <5th percentile (compared to the 10–90th centiles) [17]. Besides perinatal death [6, 11, 12, 15–18, 55], preterm birth [6, 11, 14], and other short-term adverse events are described for SGA infants (Table 1); the adjusted odds ratio (aOR) for composite neonatal morbidity can be as high as 3.22 (95% CI, 3.07–3.39) [12]. Interestingly, SGA suspicion in pregnancy is associated with better neonatal outcomes [18, 57], which turns SGA screening a cornerstone strategy for reducing antepartum fetal loss [13, 58] and mitigating neonatal morbidity ratios.

Unfortunately, the higher risk of mortality goes beyond the neonatal period. Data from Sweden show a hazard ratio (HR) of 1.37 (95% CI 1.28–1.47) of death up to 18 years old, which increased to 2.61 (95% CI 2.19–3.10) for those neonates born <3rd centile [59]. Additionally, growth restriction is
Table 1: Neonatal adverse events associated with being born SGA.

| Perinatal asphyxia            |
|-------------------------------|
| 5th-minute Apgar score <7 [10, 11, 14] |
| Admission to neonatal intensive care unit [6, 10, 11, 55] |
| Hypoglycemia requiring treatment [38, 50] |
| Phototherapy [50] |
| Respiratory distress syndrome [12, 14, 16, 50] |
| Ventilatory support [11, 12, 16, 56] |
| Necrotizing enterocolitis [12, 56] |
| Neonatal sepsis [12, 16, 50] |
| Seizure [12, 16, 18] |
| Intraventricular hemorrhage [12, 16, 18] |
| Neonatal death [11, 12, 15, 16] |

associated with a lower Bayley score, especially in communication skills domain [19], sleep disorders [52], and hyperactivity [56]. If SGA fetuses experience any degree of brain-sparing effect, the delayed motor skills and cognitive development are even more pronounced [19, 51]. Regarding metabolic repercussions, insulin and insulin resistance index (HOMA IR) are higher in SGA children at 6–8 years old and those born <3rd centile also have higher levels of leptin [22].

Evidence from adults exposed to famine in utero shows increased odds for metabolic syndrome [21] and obesity [60] in SGA newborns, perhaps in a sex-specific manner, depending on childhood nutritional parameters (especially weight gain velocity). Proportionate biometric measurements at birth were the initial observations of Barker et al. who related the ponderal index, head circumference, and birthweight <2495 g to cardiovascular mortality [23]. Although maternal undernourishment is not synonymous of SGA infant and considering that the birthweight approach has changed over time, these findings mean that adequate fetal development is the standpoint for long-term health. There is greater visceral fat thickness (in women) [61], higher fat-free soft tissue mass [62], and increased trunk and abdominal fat mass proportion of both sexes [63] in adults born SGA. These epidemiological data ground current theories of epigenetic modifications in SGA infants, leading to enriched (i.e., with increased DNA methylation) pathways involved with fat, sugar, and protein metabolism [8].

Therefore, timely recognition of SGA—still in pregnancy—is a real concern for obstetricians, perinatologists, health workers, and policymakers. Unfortunately, only a small proportion of SGA babies are suspected before birth [18, 57], leading to a lack of appropriate short- and long-term follow-up of these newborns. SGA suspicion will provide adequate management of the mother and fetus/newborn, including referencing to a specialized facility for antenatal care and delivery and individualized follow-up in childhood, adolescence, and adulthood.

3. When and How We Should Screen for Fetal Growth Restriction?

3.1. Clinical Factors. Clinical risk assessment is the first approach to antenatal care. A detailed maternal history at booking can identify several risk factors and guide referencing to tertiary care facilities.

Single maternal clinical factors demonstrate poor prediction accuracy (Table 2), and, as a result, are generally considered in a multidimensional model. Smoking, although less prevalent in the early years of the 21st century, still demonstrates effects on fetal growth [5, 6, 48] and is the most common maternal variable to compose a prediction model. Lower maternal stature and weight appear associated with SGA in some studies [11, 14, 48] but showed only 43% and 73% of sensitivity, respectively [64]. Body mass index (BMI) and maternal weight gain throughout pregnancy demonstrate an area under the (AUC) receiver operating characteristic (ROC) curve of 0.56 and 0.60, respectively [64]. The performance of symphysis-fundal height (SFH) measurement in predicting SGA newborns increases with gestational age [68], but it is not different to Leopold’s maneuvers (RR1. 32, 95% CI 0.92–1.90) [69]. However, since it is inexpensive and already part of the routine obstetrical examination, Cochrane reviewers advise its use and health professionals should associate it with some other technique or evaluation of fetal growth.

Other maternal factors have been combined differently, evidencing how SGA syndrome can be heterogeneous in distinct settings. In a multicenter international nulliparous cohort, a family history of coronary heart disease, maternal birthweight <3000 g, infertility, college student, smoking at the 2nd trimester, proteinuria, daily vigorous exercise, and diastolic blood pressure ≥80 mmHg, combined with the protective factors rising random glucose, recreational walking (≥4x/week), and Rhesus negative blood group, provided an AUC of 0.63 [6]. This same AUC (0.66, 95% CI 0.61–0.70) was achieved by combining maternal age and height, smoking, previous SGA infant, and chronic hypertension in Spain [70]. In the United Kingdom, a logistic regression model included maternal height, weight, parity, ethnic background, smoking, and previous history of pre-eclampsia or SGA [71]. In this model, maternal factors evaluation between 35 and 37 w have had similar AUC for delivery within two weeks (0.744; 95% CI 0.731–0.756) and term delivery (0.712; 95% CI 0.700–0.725) for SGA without pre-eclampsia.

3.2. Ultrasound Scans. Adding ultrasound scan (US) parameters to maternal clinical factors improves the performance of prediction models, although not consistently [6, 71]. Crown-rump length (CRL) [43]; nuchal translucency (NT) [43]; head circumference (HC) [6]; abdominal circumference (AC) [6, 72]; AC growth velocity (ACGV) [72, 73]; femur length (FL) [74]; estimated fetal weight (EFW) [32, 44, 71, 73, 75, 76]; uterine arteries pulsatility index (UtA-PI) or resistance (UtA-R1) index, or notches [6, 32, 71, 76]; umbilical artery PI (UA-PI); middle cerebral artery PI (MCA-PI); cerebral-placental ratio (CPR: MCA-PI/UA-PI) [32, 66, 76]; and umbilical vein blood flow (UVBF) [32] were studied for SGA prediction. Except for NT, the lower the fetal biometry, the higher the odds for SGA; in general, there is a trend towards better US predictive
accuracy for lower birthweight centiles (especially <3rd) [67, 76]. Unfortunately, participants' selection criteria, study protocol of follow-up, and outcome measures differ between studies, precluding interpretation and evaluation of US in clinical practice [67]. In Table 2, predictive accuracy measures of EFW and AC are shown.

In the 1st trimester, decreased values of NT were associated to lesser odds for SGA (OR 0.79; 95% CI 0.70–0.89), but the CRL has shown no relationship (OR 0.99, 95% CI 0.99–1.00) [43]. In the 2nd trimester, McCowan et al. [6] demonstrated that only a limited increase in AUC (from 0.66 to 0.73) was observed with the addition of 20 w US data to maternal data: HC z-score <10th centile, AC z-score <10th centile, and UtA-RI ≥ 0.05. The higher the UtA-RI, the higher the OR for SGA, reaching 4.56 (95% CI 2.45 to 8.48) when 0.8–1.0. At 35–37 w, Fadigas et al. [71] have combined maternal variables with EFW z-score, which improved AUC from 0.81 (95% CI 0.802–0.824) to 0.98 (95% CI 0.98–0.98) for delivering an SGA infant <3rd centile in less than two weeks. In this cohort, adding mean arterial pressure and UtA-PI has not improved the prediction performance (AUC 0.98; 95% CI 0.98–0.99).

Interestingly, a single measurement is better than longitudinal follow-up [32, 67, 72, 73, 75]. In the 2nd trimester, the femur length <5th centile is associated with increased odds for IUAGR or SGA (3.24, 95% CI 2.34–4.48) [74]. The performance of EFW <10th centile at 35–37 w in predicting delivery within two weeks is better for SGA <3rd (83%; 95% CI 80–86) than for SGA <10th (69%; 95% CI 67–71) [76]. Although EFW <10th centile is related to a higher risk of any adverse perinatal outcomes [77], it demonstrates poor prediction performance (26%; 95% CI 28–30; for SGA <3rd delivering in 2 w) [76]. In another example, Triunfo et al. have demonstrated better prediction performance of EFW at 37 w for SGA <3rd (0.85; 95% CI 0.82–0.89), when compared to the 4–10th centiles (0.93; 95% CI 0.89–0.97) but reached a disappointing AUC of 0.54 (95% CI 0.48–0.61) for predicting adverse perinatal outcomes [32]. This is also true for AC cross-sectional evaluation at 32 w seemed compared to ACGV (difference from 32 w results and 2nd trimester) [72]. The detection rate (DR) of SGA <10th centile was 49.1 (95% CI 44.2–52.8; false positive rate, FPR, 10%) and 81.2 (95% CI 75.3–88.1) for SGA <3rd centile or suspected before birth by abnormal Doppler results. This finding partially contradicts the Pregnancy Outcome Prediction (POP) Study, which found a relative risk of 17.6 (95% CI 9.2–34.0) for delivering an SGA infant when both EFW and ACGV (between 28 and 36 w) were <10th centile [73]. In this study, the sensitivity of EFW <10th centile was higher with universal screening for SGA <10th (57%) or <3rd centile (77%) than with clinically oriented US evaluation (20% and 32%, respectively) [73].

More recently, magnetic resonance imaging (MRI) has been explored in maternal-fetal surveillance. Carlin et al. [78] have demonstrated no difference in EFW <3rd or <5th centile by US or MRI before delivery (48 h). However, DR of SGA <10th centile was superior with MRI (100.0; 95% CI 81.5–100.0, FPR of 10%) than the US (77.8; 95% CI 52.4–93.6, FPR 10%).

### 3.3. Biomarkers

Biomarker measurements of placentation functioning-related substances have had significant development in the last three decades. Many of these compounds are also involved with antenatal detection of chromosomal anomalies, or preeclampsia, such as PAPP-A, AFP, PlGF, or sFlt-1 [41] (Table 2). Studies from the mid 1980s have evaluated the human placental lactogen (hPL), when it demonstrated a diagnostic odds ratio (DOR) of 4.78 (95% CI 3.21–7.13), whereas more recent data focus on angiogenic biomarkers [44].

The AFP: PAPP-A ratio >10 at 12 w of pregnancy provided a risk ratio of 3.74 (95% CI 2.3–6.09) for SGA <3rd centile [34]. In early 2nd trimester (15 w), serum levels of PAPP-A, PIgf, and insulin are significantly lower in SGA pregnancies [79], while increased plasma levels of vascular growth factor (VEGF) between 34 and 37 weeks were related to a lower chance of restricted fetuses (OR 0.8; 95% CI 0.71–0.92) [80]. Conversely, a model built by EFW, UtA-PI, and PIgf at 35–37w has provided an AUC 0.883 (95% CI 0.867–0.899) [81].

PlGF has consistently lower levels in SGA pregnancies, in 2nd and 3rd trimesters [82–84], especially for BW <5th or <10th centiles. For higher sFlt-1/PIgf ratios, there is better AUC for preeclampsia-associated SGA [40, 41]. These findings point in the direction of angiogenesis-mediated pathophysiology of SGA, especially when there are Doppler abnormal parameters [37]. Unfortunately, PlGF shows poor accuracy to be implemented in clinical practice: the combined AUC was 0.66 (95% CI 0.44–0.87) for FGR prediction [65]. Perhaps, this finding is due to the diverse PlGF measurements and FGR definitions used by the studies included in the systematic review, which considered either

| Predictive factors | AUC         | S (95% CI) | Sp (95% CI) | When               |
|--------------------|-------------|-----------|-------------|--------------------|
| Maternal height    | 0.59        | 0.43 (0.27–0.60) | 0.70 (0.53–0.83) | At booking         |
| Maternal weight    | 0.57        | 0.73 (0.60–0.83)  | 0.35 (0.23–0.51) | At booking         |
| Maternal weight gain | 0.60       | 0.50 (0.42–0.59) | 0.66 (0.57–0.73) | At booking         |
| PAPP-A             | 0.16 (0.14–0.19) | 0.90 (0.89–0.90) | 1st trimester    |
| PIgf               | 0.49 (0.44–0.53) | 0.64 (0.63–0.66) | 2nd trimester    |
| Cerebroplacental ratio | 0.66       | 0.43 (0.39–0.47) | 0.94 (0.84–0.98) | 3rd trimester    |
| Estimated fetal weight | 0.79       | 0.38 (0.31–0.46) | 0.95 (0.93–0.97) | >32 w             |
| Abdominal circumference | 0.92       | 0.35 (0.20–0.52) | 0.97 (0.95–0.98) | >32 w             |

*aMCA-PI/UA-PI <10th centile or ≤1.08; bestimated fetal weight <10th centile for gestational age. AUC: area under the receiver operator characteristic curve; S: sensitivity; Sp: specificity; PAPP-A: pregnancy-associated plasma protein-A; PIgf: placentation growth factor."
the estimated fetal weight, birth weight, or the presence of additional findings of severity (e.g., oligohydramnios).

After all, better accuracy was achieved by combining multiple maternal, ultrasonographic, and biochemical clinical factors. In an international cohort of nulliparous women [79], PI GF has had an AUC of 0.84 (95% CI 0.78–0.89) for hypertensive-SGA when combined with smoking, proteinuria, uterine artery Doppler, PAPP-A, and triglycerides. In the 2nd trimester (19–24 w), PI GF and AFP, combined with maternal factors and fetal biometry, made up an AUC of 0.96 for birth below 32 weeks in SGA newborns [31].

4. Conclusions

Fetal growth restriction is related to adverse outcomes in the perinatal period, childhood, and adulthood; the estimated actual burden of SGA [13, 25] might be even higher in the next few years. Starting antenatal care at early pregnancy leads to adequate risk management and additional evaluation assessment, with US or biomarkers. The “inverted pyramid” of prenatal care claims attention to the early pregnancy risk evaluation [85], and we strongly believe screening is the first step towards a better disease diagnosis and management. Screening for FGR is a major cornerstone for coordinating care from pregnancy to the postpartum period, which affects both maternal and fetal/neonatal outcomes [86]. The low velocity in which stillbirth and neonatal death rates have decreased in the past 30 years is an “unfinished agenda” [86].

Although the cost-effectiveness of short-term pregnancy-related adverse outcomes is still a matter of debate [87], little is known about the future consequences of a health policy devoted to primary prevention of pregnancy-associated illness in a long-term [49, 59, 88]. On the contrary, the lack of definition of a high-risk group of women that could benefit from a more directed approach delays scientific and clinical evaluation of SGA. As maternal factors have a different magnitude between settings and placental biomarkers are not a reality in most LMIC countries, currently, the 3rd trimester US seems the best approach for SGA prediction [44]. In near future, we envision an integrated approach of pregnant women at booking [85], aiming a transgenerational [49] effect of long-term health, both at individual and populational levels.

Disclosure

This manuscript is part of the PhD thesis of Debora F Leite under the tutorial of Jose G. Cecatti, presented to the Postgraduate Program of Obstetrics and Gynecology from the University of Campinas, Brazil. The content is solely the responsibility of the authors and does not necessarily represent the official views of CAPES. It did not influence the content of the manuscript. CAPES had no role in the authors’ decision of drafting or submitting this manuscript.

Conflicts of Interest

The authors declare that there are no conflicts of interest at all.

Authors’ Contributions

DFBL has proposed the review and drafted the first manuscript. JGC has supervised and checked the drafting. Both authors have read and agreed with this submission.

Acknowledgments

The authors kindly thank Prof. Renato Passini Júnior and Prof. Maria Laura Costa for their pertinent suggestions to this manuscript. DFBBL was supported by the Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES; process number 88881.134512/2016-01) while visiting the University College Cork (Cork, Ireland).

References

[1] J. Warkany, B. B. Monroe, and B. Sutherland, "Intrauterine growth retardation," The American Journal of Diseases of Children, vol. 102, pp. 249–279, 1961.
[2] P. Gruenwald, "Chronic fetal distress and placental insufficiency," Neonatology, vol. 5, no. 3-4, pp. 215–265, 1963.
[3] P. Gruenwald, “Growth of the human fetus. I. Normal growth and its variation,” *American Journal of Obstetrics and Gynecology*, vol. 94, no. 8, pp. 1112–1119, 1966.

[4] W. L. Rumbolz, M. C. Edwards, and L. S. McGoogan, “The small full term infant and placental insufficiency,” *Obstetrical & Gynecological Survey*, vol. 16, no. 5, pp. 616–618, 1961.

[5] M. Abraham, S. Alramadhan, C. Iniguez et al., “A systematic review of maternal smoking during pregnancy and fetal measurements with meta-analysis,” *PLoS One*, vol. 12, no. 2, Article ID e0170946, 2017.

[6] M. L. M. E. McCowan, J. M. D. Hompson, R. S. Taylor et al., “A systematic review of small-for-gestational-age birthweight standards for identification of perinatal mortality and morbidity,” *American Journal of Obstetrics and Gynecology*, vol. 214, no. 4, pp. 509.e1–509.e7, 2016.

[7] H. Mendez-Figueroa, S. P. Chauhan, T. Barrett, V. T. T. Tuong, C. Pedroza, and S. C. Blackwell, “Population versus customized growth curves: prediction of composite neonatal morbidity,” *American Journal of Perinatology*, vol. 36, no. 8, pp. 818–827, 2019.

[8] A. C. Lee, N. Kozuki, S. Cousens et al., “Estimates of burden and consequences of infants born small for gestational age in low and middle income countries with INTERGROWTH-21st standard: analysis of CHERG datasets,” *BMJ*, vol. 358, article j3677, 2017.

[9] A. G. Odibo, C. Nwabuobi, L. Odibo, K. Leavitt, S. Obican, and M. G. Tuuli, “Customized fetal growth standard compared with the INTERGROWTH-21st century standard at predicting small-for-gestational-age neonates,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 97, no. 11, pp. 1381–1387, 2018.

[10] J. Gardosi and A. Francis, “Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles,” *American Journal of Obstetrics and Gynecology*, vol. 201, no. 1, pp. e1–e825, 2009.

[11] D. D. McIntire, S. L. Bloom, B. M. Casey, and K. J. Leveno, “Birth weight in relation to morbidity and mortality among newborn infants,” *New England Journal of Medicine*, vol. 340, no. 16, pp. 1234–1238, 1999.

[12] R. Bukowski, N. I. Hansen, M. Willinger et al., “Fetal growth and risk of stillbirth: a population-based case-control study,” *PLoS Medicine*, vol. 11, no. 4, Article e1001633, 2014.

[13] P. G. Lindqvist and J. Molin, “Does antenatal identification of small-for-gestational-age fetuses significantly improve their outcome?,” *Ultrasound in Obstetrics and Gynecology*, vol. 25, no. 3, pp. 258–264, 2005.

[14] S. Meher, E. Hernandez-Andrade, S. N. Basheer, and C. Lees, “Impact of cerebral redistribution on neurodevelopmental outcome in small-for-gestational-age or growth-restricted babies: a systematic review,” *Ultrasound in Obstetrics & Gynecology*, vol. 46, no. 4, pp. 398–404, 2015.

[15] E. Murray, M. Fernandes, M. Fazel, S. H. Kennedy, J. Villar, and A. Stein, “Differential effect of intrauterine growth restriction on childhood neurodevelopment: a systematic review,” *BJOG: An International Journal of Obstetrics & Gynecology*, vol. 122, no. 8, pp. 1062–1072, 2015.

[16] N. Wang, X. Wang, Q. Li et al., “The famine exposure in early life and metabolic syndrome in adulthood,” *Clinical Nutrition*, vol. 36, no. 1, pp. 253–259, 2017.

[17] N. I. Hansen, M. Willinger et al., “Differential effect of intrauterine growth restriction on childhood neurodevelopment: a systematic review,” *BJOG: An International Journal of Obstetrics & Gynecology*, vol. 122, no. 8, pp. 1062–1072, 2015.

[18] N. Wang, X. Wang, Q. Li et al., “The famine exposure in early life and metabolic syndrome in adulthood,” *Clinical Nutrition*, vol. 36, no. 1, pp. 253–259, 2017.

[19] E. N. Evangelidou, V. I. Giapros, A. S. Challa, D. N. Kiortsis, A. A. Tsatsoulis, and S. K. Andronikou, “Serum adiponectin levels, insulin resistance, and lipid profile in children born small for gestational age are affected by the severity of growth retardation at birth,” *European Journal of Endocrinology*, vol. 156, no. 2, pp. 271–277, 2007.

[20] D. S. Baskir, C. Osmanov, S. J. Simmons, and G. A. Wield, “The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life,” *BMJ*, vol. 306, no. 6875, pp. 422–426, 1993.

[21] L. O. Lubchenco, C. Hansman, M. Dressler, and E. Boyd, “Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation,” *Pediatrics*, vol. 32, pp. 793–800, 1963.

[22] A. C. Lee, J. Katz, H. Blencowe et al., “National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010,” *The Lancet Global Health*, vol. 1, no. 1, pp. e26–e36, 2013.

[23] World Health Organization, *Expert Group on Prematurity World Health Organization*, Final report, World Health Organization, Geneva, Switzerland, 1950.

[24] F. C. Battaglia and L. O. Lubchenco, “A practical classification of newborn infants by weight and gestational age,” *The Journal of Pediatrics*, vol. 71, no. 2, pp. 159–163, 1967.

[25] L. M. E. McCowan, “INTERGROWTH-21st vs customized growth curves: prediction of composite neonatal morbidity,” *American Journal of Perinatology*, vol. 36, no. 8, pp. 818–827, 2019.

[26] L. M. E. McCowan, “INTERGROWTH-21st vs customized growth curves: prediction of composite neonatal morbidity,” *American Journal of Perinatology*, vol. 36, no. 8, pp. 818–827, 2019.

[27] D. S. Baskir, C. Osmanov, S. J. Simmons, and G. A. Wield, “The relation of small head circumference and thinness at birth to death from cardiovascular disease in adult life,” *BMJ*, vol. 306, no. 6875, pp. 422–426, 1993.
gestation,” *Ultrasound in Obstetrics & Gynecology*, vol. 49, no. 3, pp. 364–371, 2017.

[33] I. Brosens, R. Pijnenborg, L. Vercruysse, and R. Romero, “The “great obstetrical syndromes” are associated with disorders of deep placentaion,” *American Journal of Obstetrics and Gynecology*, vol. 204, no. 3, pp. 193–201, 2011.

[34] A. E. Hughes, U. Sovio, F. Gaccioli, E. Cook, D. S. Charnock-Jones, and G. C. S. Smith, “The association between first trimester AFP to PAPP-A ratio and placenta-related adverse pregnancy outcome,” *Placenta*, vol. 81, pp. 25–31, 2019.

[35] S. Triunfo, S. Lobmaier, M. Parra-Saavedra et al., “Angiogenic factors at diagnosis of late-onset small-for-gestational age and histological placental underperfusion,” *Placenta*, vol. 35, no. 6, pp. 398–403, 2014.

[36] A. Hauspurg, E. K. Redman, V. Assibey-Mensah et al., “Placental findings in non-hypertensive term pregnancies and association with future adverse pregnancy outcomes: a cohort study,” *Placenta*, vol. 74, pp. 14–19, 2018.

[37] H. G. Herman, E. Barber, R. Gasnier et al., “Placental pathology and neonatal outcome in small for gestational age pregnancies with and without abnormal umbilical artery doppler flow,” *European Journal of Obstetrics & Gynecology and Reproductive Biology*, vol. 222, pp. 52–56, 2018.

[38] K. M. Chisholm and A. K. Folkins, “Placental and clinical characteristics of term small-for-gestational-age neonates: a case-control study,” *Pediatric and Developmental Pathology*, vol. 19, no. 1, pp. 37–46, 2016.

[39] M. Parra-Saavedra, F. Crovetto, S. Triunfo et al., “Association of doppler parameters with placental signs of underperfusion in late-onset small-for-gestational-age pregnancies,” *Ultrasound in Obstetrics & Gynecology*, vol. 44, no. 3, pp. 330–337, 2014.

[40] T. M. MacDonald, C. Tran, T. J. Kaitu-u-Lino et al., “Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study,” *BMC Pregnancy and Childbirth*, vol. 18, no. 1, 2018.

[41] L. H. Bækggaard Thorsen, L. B. Andersen, A. Birukov et al., “Prediction of birth weight small for gestational age with and without preeclampsia by angiogenic markers: an odense child cohort study,” *The Journal of Maternal-Fetal & Neonatal Medicine*, pp. 1–8, 2018.

[42] U. Cakir, D. Yildiz, D. Kalvecigolu et al., “Placenta, secret witness of infant morbidities: the relationship between placental histology and outcome of the premature infant,” *Turkish Journal of Pathology*, vol. 35, pp. 28–35, 2018.

[43] R. K. Morris, A. Bilagi, P. Devani, and M. D. Kilby, “Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis,” *Prenatal Diagnosis*, vol. 37, no. 3, pp. 253–265, 2017.

[44] A. E. Heazell, D. J. Hayes, M. Whitworth, Y. Takwoingi, S. E. Bayliss, and C. Davenport, “Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants,” *The Cochrane Database of Systematic Reviews*, vol. 5, article CD012245, 2019.

[45] L. McCowan and R. P. Horgan, “Risk factors for small for gestational age infants,” *Best Practice & Research Clinical Obstetrics & Gynaecology*, vol. 23, no. 6, pp. 779–793, 2009.

[46] E. Bartsch, K. E. Medcalf, A. L. Park, and J. G. Ray, “Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies,” *BMJ*, vol. 353, article i1753, 2016.

[47] B. Koulilai, M. A. Oudijk, T. A. J. Nijman, B. W. J. Mol, and E. Pajkrt, “Risk assessment and management to prevent preterm birth,” *Seminars in Fetal and Neonatal Medicine*, vol. 21, no. 2, pp. 80–88, 2016.

[48] C. Lesmes, D. M. Gallo, Y. Saidi, L. C. Poon, and K. H. Nicolaides, “Prediction of small-for-gestational-age neonates: screening with uterine artery doppler and mean arterial pressure at 19–24 weeks,” *Ultrasound in Obstetrics & Gynecology*, vol. 46, no. 3, pp. 332–340, 2015.

[49] Á. Sepúlveda-Martínez, M. Rodríguez-López, F. Paz-y-Miró et al., “Transgenerational transmission of small for gestational age,” *Ultrasound in Obstetrics & Gynecology*, vol. 53, no. 5, pp. 623–629, 2019.

[50] B. Stewart, A. Karahalios, R. Pszczola, and J. Said, “Moderate to late preterm intrauterine growth restriction: a retrospective, observational study of the indications for delivery and outcomes in an Australian perinatal centre,” *Australian and New Zealand Journal of Obstetrics and Gynaecology*, vol. 58, no. 3, pp. 306–314, 2018.

[51] N. Korkalainen, J. Räisänen, T. Kaukola, H. Kallankari, M. Hallman, and K. Mäikäläinen, “Fetal hemodynamics and adverse outcome in primary school-aged children with fetal growth restriction: a prospective longitudinal study,” *Acta Obstetricia et Gynecologica Scandinavica*, vol. 96, no. 1, pp. 69–77, 2017.

[52] K. M. Stangenes, M. Hysing, S. K. Fevang et al., “Prenatal and neonatal factors predicting sleep problems in children born extremely preterm or with extremely low birthweight,” *Frontiers in Pediatrics*, vol. 6, pp. 1–9, 2018.

[53] J. E. Lawn, H. Blencowe, R. Pattinson et al., “Stillbirths: where? When? Why? How to make the data count?,” *The Lancet*, vol. 377, no. 9775, pp. 1448–1463, 2011.

[54] J. Gardosi, S. M. Kady, P. McGeown, A. Francis, and A. Tonks, “Classification of stillbirth by relevant condition at death (ReCoDe): population based cohort study,” *BMJ*, vol. 331, no. 7525, pp. 1113–1117, 2005.

[55] A. Ciobanou, S. Jabak, H. De Castro, L. Frei, R. Akolekar, and K. H. Nicolaides, “Biomarkers of impaired placentation at 35–37 weeks’ gestation in the prediction of adverse perinatal outcome,” *Ultrasound in Obstetrics & Gynecology*, vol. 54, no. 1, pp. 79–86, 2019.

[56] M. B. Graz, J.-F. Tolsa, and C. J. F. Fumex, “Being small for gestational age: does it matter for the neurodevelopment of premature infants? A cohort study,” *PloS One*, vol. 10, no. 5, Article ID e0125769, 2015.

[57] J.-W. Verlijsdonk, B. Winkens, K. Boers, S. Scherjon, and F. Roumen, “Suspected versus non-suspected small-for-gestational-age fetuses at term: perinatal outcomes,” *The Journal of Maternal-Fetal & Neonatal Medicine*, vol. 25, no. 7, pp. 938–943, 2012.

[58] R. Pattinson, K. Kerber, E. Buchmann et al., “Stillbirths: how can health systems deliver for mothers and babies?,” *The Lancet*, vol. 377, no. 9777, pp. 1610–1623, 2011.

[59] J. W. Verlijsdonk, B. Winkens, K. Boers, S. Scherjon, and F. Roumen, “Suspected versus non-suspected small-for-gestational-age fetuses at term: perinatal outcomes,” *The Journal of Maternal-Fetal & Neonatal Medicine*, vol. 25, no. 7, pp. 938–943, 2012.

[60] R. Pattinson, K. Kerber, E. Buchmann et al., “Stillbirths: how can health systems deliver for mothers and babies?,” *The Lancet*, vol. 377, no. 9777, pp. 1610–1623, 2011.
adulthood: the 1982 Pelotas (Brazil) birth cohort study," International Journal of Obesity, vol. 40, no. 1, pp. 14–21, 2016.

[62] A. Prioreschi, R. J. Munthali, J. Kagura et al., “The associations between adult body composition and abdominal adiposity outcomes, and relative weight gain and linear growth from birth to age 22 in the birth to twenty plus cohort, south africa,” PLoS One, vol. 13, no. 1, Article ID e0190483, 2018.

[63] G. V. Araújo de França, M. C. Restrepo-Méndez, C. Loret de Mola, and G. C. Victora, “Size at birth and abdominal adiposity in adults: a systematic review and meta-analysis,” Obesity Reviews, vol. 15, no. 2, pp. 77–91, 2014.

[64] E. Goto, “Maternal anthropometry to predict small for gestational age: a meta-analysis,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 203, pp. 193–198, 2016.

[65] A. Conde-Agudelo, A. Papageorghiou, S. Kennedy, and J. Villar, “Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 120, no. 6, pp. 681–694, 2013.

[66] A. Conde-Agudelo, J. Villar, S. H. Kennedy, and A. T. Papageorghiou, “Predictive accuracy of cerebroplacental ratio for adverse perinatal and neurodevelopmental outcomes in suspected fetal growth restriction: systematic review and meta-analysis,” Ultrasound in Obstetrics & Gynecology, vol. 52, no. 4, pp. 430–441, 2018.

[67] J. Caradeux, R. J. Martínez-Portilla, A. Pequero, A. Sotiriadis, and F. Figueras, “Diagnostic performance of third-trimester ultrasound for the prediction of late-onset fetal growth restriction: a systematic review and meta-analysis,” American Journal of Obstetrics and Gynecology, vol. 220, no. 5, pp. 449.e19–459.e19, 2019.

[68] A. Pay, J. Froen, A. Staff, B. Jacobsson, and H. Gjessing, “Prediction of small-for-gestational-age status by symphysion-fundus height: a registry-based population cohort study,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 123, no. 7, pp. 1167–1173, 2016.

[69] J. R. Peter, J. J. Ho, J. Valliapan et al., “Symphysial fundal height (SFH) measurement in pregnancy for detecting abnormal fetal growth,” Cochrane Database of Systematic Reviews, vol. 2015, 2015.

[70] J. Miranda, M. Rodriguez-Lopez, S. Triunfo et al., “Prediction of fetal growth restriction using estimated fetal weight vs a combined screening model in the third trimester,” Ultrasound in Obstetrics & Gynecology, vol. 50, no. 5, pp. 603–611, 2017.

[71] C. Fadigas, L. Guerra, S. Garcia-Tizon Larroca, L. C. Poon, and K. H. Nicolaides, “Prediction of small-for-gestational-age neonates: screening by uterine artery doppler and mean arterial pressure at 35–37 weeks,” Ultrasound in Obstetrics & Gynecology, vol. 45, no. 6, pp. 715–721, 2015.

[72] J. Caradeux, E. Eixarch, E. Mazarico, T. R. Basuki, E. Gratacós, and F. Figueras, “Second- to third-trimester longitudinal growth assessment for prediction of small-for-gestational age and late fetal growth restriction,” Ultrasound in Obstetrics & Gynecology, vol. 51, no. 2, pp. 219–224, 2018.

[73] U. Sovio, I. R. White, A. Dacey, D. Pasupathy, and G. C. S. Smith, “Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the pregnancy outcome prediction (POP) study: a prospective cohort study,” The Lancet, vol. 386, no. 10008, pp. 2089–2097, 2015.

[74] V. D’Ambrosio, F. Vena, C. Marchetti et al., “Midtrimester isolated short femur and perinatal outcomes: a systematic review and meta-analysis,” Acta Obstet Gynecol Scand, vol. 98, no. 1, pp. 11–17, 2019.

[75] A. L. Tarca, E. Hernandez-Andrade, H. Ahn et al., “Single and serial fetal biometry to detect preterm and term small- and large-for-gestational-age neonates: a longitudinal cohort study,” PLoS One, vol. 11, no. 11, Article ID e0164161, 2016.

[76] R. Akolekar, A. M. Panaitescu, A. Ciobanu, A. Syngelaki, and K. H. Nicolaides, “Two-stage approach for prediction of small for gestational age neonates and adverse perinatal outcome by routine ultrasound examination at 35–37 weeks’ gestation,” Ultrasound in Obstetrics & Gynecology, 2019.

[77] D. Kabiri, R. Romero, D. W. Gu dicha et al., “Prediction of adverse perinatal outcomes by fetal biometry: a comparison of customized and population-based standards,” Ultrasound in Obstetrics & Gynecology, 2019.

[78] A. Carlin, C. Kadij, R. De Angelis, M. M. Can nie, and J. C. Jani, “Prenatal prediction of small-for-gestational age neonates using MR imaging: comparison with conventional 2D ultrasound,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 32, no. 10, pp. 1673–1681, 2019.

[79] L. M. E. McCowan, J. M. D. Thompson, R. S. Taylor et al., “Prediction of small for gestational age infants in healthy nulliparous women using clinical and ultrasound risk factors combined with early pregnancy biomarkers,” PLoS One, vol. 12, no. 1, Article ID e0169311, 2017.

[80] P. Kumarathanas, G. Williams, A. Bielecki et al., “Characterization of maternal plasma biomarkers associated with delivery of small and large for gestational age infants in the MIREC study cohort,” PLoS One, vol. 13, no. 11, Article ID e0204863, 2018.

[81] N. Valiño, G. Giunta, D. M. Gallo, R. Akolekar, and K. H. Nicolaides, “Biophysical and biochemical markers at 35–37 weeks’ gestation in the prediction of adverse perinatal outcome,” Ultrasound in Obstetrics & Gynecology, vol. 47, no. 2, pp. 203–209, 2016.

[82] H. Sherrill, L. Dunn, V. Clifton, and S. Kumar, “Systematic review of maternal placental growth factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 225, pp. 26–34, 2018.

[83] I. Furuta, T. Umazume, T. Kojima et al., “Serum placental growth factor and soluble fms-like tyrosine kinase 1 at midgestation in healthy women: association with small-for-gestational-age neonates,” Journal of Obstetrics and Gynaecology Research, vol. 43, no. 7, pp. 1152–1158, 2017.

[84] S. Kwiatkowski, M. Bednarek-Jędrzejek, J. Ksel et al., “SFlt-1/PIGF and doppler ultrasound parameters in SGA pregnancies with confirmed neonatal birth weight below 10th percentile,” Pregnancy Hypertension, vol. 14, pp. 79–85, 2018.

[85] K. H. Nicolaides, “Turning the pyramid of prenatal care,” Fetal Diagnosis and Therapy, vol. 29, no. 3, pp. 183–196, 2011.

[86] L. de Bernis, M. V. Kinney, W. Stones et al., “Stillbirths: ending preventable deaths by 2030,” The Lancet, vol. 387, no. 10019, pp. 703–716, 2016.

[87] C. Meads, J. S. C., S. M. et al., “Methods of prediction and effectiveness literature with economic modelling,” Health Technology Assessment, vol. 12, no. 6, pp. 1–270, 2008.

[88] J. C. Jani, “Prenatal prediction of small-for-gestational age and late fetal growth restriction,” Ultrasound in Obstetrics & Gynecology, vol. 14, pp. 79–85, 2018.